Ticker > Company >

Medicamen Organics share price

Medicamen Organics Ltd.

NSE: MEDIORG SECTOR: Pharmaceuticals & Drugs  4.95 K   6   0

33.00
-1.20 (-3.51%)
NSE: 09 Sep 03:31 PM

Price Summary

Today's High

₹ 33.5

Today's Low

₹ 32.55

52 Week High

₹ 72.6

52 Week Low

₹ 19.6

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

38.61 Cr.

Enterprise Value

50.71 Cr.

No. of Shares

1.17 Cr.

P/E

11.8

P/B

1.5

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  21.99

CASH

0.55 Cr.

DEBT

12.66 Cr.

Promoter Holding

59.73 %

EPS (TTM)

₹  2.8

Sales Growth

14.11%

ROE

19.9 %

ROCE

16.6%

Profit Growth

148.02 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.11%
3 Year0.3%
5 YearNA

Profit Growth

1 Year148.02%
3 Year100.54%
5 YearNA

ROE%

1 Year19.9%
3 Year10.87%

ROCE %

1 Year16.6%
3 Year10.28%

Debt/Equity

0.8335

Price to Cash Flow

-10.47

Interest Cover Ratio

6.2345

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 59.73 0.00
Sep 2024 59.69 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company’s PEG ratio is 0.161607465668318.
  • The company has an efficient Cash Conversion Cycle of -32.9914 days.
  • The company has a high promoter holding of 59.73%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 13.1657637931737.
  • Promoter stake has increased from 0% to 59.69% in the last 1 quarter.

 Limitations

  • The company has shown a poor revenue growth of 0.298011539018694% for the Past 3 years.
  • Company has high debtor days of 198.3621.
  • Company has negative cash flow from operations of -3.6885.
  • The company has a low EBITDA margin of 0% over the past 5 years.

Quarterly Result (All Figures in Cr.)

 Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 25.05 20.98 22.15 25.27
Total Expenditure 23.41 19.78 20.28 20.53
Operating Profit 1.63 1.2 1.87 4.74
Other Income 0.01 0.21 0.82 0.02
Interest 0.48 0.47 0.61 0.65
Depreciation 0.68 0.68 0.71 0.72
Exceptional Items 0 0 0 0
Profit Before Tax 0.49 0.26 1.36 3.39
Tax 0.19 0.15 0.39 0.98
Net Profit 0.3 0.1 0.97 2.4
Adjusted EPS (Rs.) 0.5 0.17 1.62 2.8

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 6 6 6 8.6
Total Reserves 1.47 2.01 2.98 6.58
Borrowings 0.64 0.64 0.33 0.16
Other N/C liabilities 1.17 1.34 1.38 1.4
Current liabilities 17.07 17.54 21.9 21.84
Total Liabilities 26.34 27.54 32.59 38.58
Assets
Net Block 11.35 11.29 10.87 10.35
Capital WIP 0 0 0 0.15
Intangible WIP 0 0 0 0
Investments 0 0 0 0
Loans & Advances 0.27 0.82 0.83 0.75
Other N/C Assets 0 0 0.02 0.02
Current Assets 14.72 15.43 20.87 27.31
Total Assets 26.34 27.54 32.59 38.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 0.49 0.26 1.36 3.39
Adjustment 1.57 1 0.53 1.5
Changes in Assets & Liabilities -3.18 -1.15 -2.43 -8.37
Tax Paid -0.05 -0.07 -0.05 -0.21
Operating Cash Flow -1.16 0.04 -0.58 -3.69
Investing Cash Flow -0.02 -0.59 -0.28 -0.33
Financing Cash Flow 1.27 0.18 0.94 4.01
Net Cash Flow 0.09 -0.37 0.07 -0.01

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Mar 2025%
promoters 59.69 59.73
ashutosh gupta 5.02 5.05
bal kishan gupta 52.16 52.16
ishaan gupta 0.06 0.06
ritu gupta . 2.45 2.45
PARTICULARS Sep 2024% Mar 2025%
investors 40.31 40.27
akilandeswari selvamurthy... 1.06 1.37
pawan kumar gupta 1.37 1.37
sb opportunities fund i 3.69 3.69
shivani chopra 5.13 5.13
rajasthan global securiti... 1.91 -

Annual Reports

Title Link
Title Link
Annual Report 2025

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Medicamen Organics Stock Price Analysis and Quick Research Report. Is Medicamen Organics an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Medicamen Organics. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Medicamen Organics has a PE ratio of 11.8038416139071 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Medicamen Organics has ROA of 6.7563% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Medicamen Organics has a Current ratio of 1.2508.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Medicamen Organics has a ROE of 19.8983%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Medicamen Organics has a Debt to Equity ratio of 0.8335 which means that the company has low proportion of debt in its capital.

  • Sales growth: Medicamen Organics has reported revenue growth of 14.1084% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Medicamen Organics for the current financial year is 18.7470569846904%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Medicamen Organics is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Medicamen Organics is Rs 2.7957. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Medicamen Organics in Ticker for free. Also, one can get the intrinsic value of Medicamen Organics by using Valuation Calculators, which are available with a Finology ONE subscription. 

Medicamen Organics FAQs

Q1. What is Medicamen Organics share price today?
Ans: The current share price of Medicamen Organics is Rs 33.

Q2. What is the market capitalisation of Medicamen Organics?
Ans: Medicamen Organics has a market capitalisation of Rs 38.61 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Medicamen Organics?
Ans: The PE ratio of Medicamen Organics is 11.8038416139071 and the P/B ratio of Medicamen Organics is 1.50093467295543, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Medicamen Organics share?
Ans: The 52-week high share price of Medicamen Organics is Rs 72.6, and the 52-week low share price of Medicamen Organics is Rs 19.6.

Q5. Does Medicamen Organics pay dividends?
Ans: Currently, Medicamen Organics does not pay dividends. Dividend yield of Medicamen Organics is around 0%.

Q6. What are the face value and book value of Medicamen Organics shares?
Ans: The face value of Medicamen Organics shares is Rs 10, while the book value per share of Medicamen Organics is around Rs 21.9863. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Medicamen Organics?
Ans: Medicamen Organics has a total debt of Rs 12.6565 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Medicamen Organics?
Ans: The ROE of Medicamen Organics is 19.8983% and ROCE of Medicamen Organics is 16.6046%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Medicamen Organics a good buy for the long term?
Ans: The Medicamen Organics long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Medicamen Organics undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Medicamen Organics appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Medicamen Organics’s financials?
Ans: You can review Medicamen Organics’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Medicamen Organics
X